The SME initial public offering (IPO) of Vijayawada-headquartered multi-specialty diagnostic and imaging services provider Pramodini Medicare Limited officially locked its bidding windows today, Friday, August 14, 2026.

Following an opening baseline on Day 1 (0.75x) and Day 2 (0.91x), the final afternoon recorded a solid surge across institutional, high-net-worth (HNI), and retail investor tranches. By the drop of the terminal shutters at 5:00 PM IST across the NSE SME platform, central exchange matching registries compiled valid electronic application tokens for 1,60,95,600 equity shares against a net public offer pool of 41,54,400 equity shares (excluding anchor allocations and the market maker quota).

This brought the final overall subscription level to 3.87 times.

Priced within an official price band parameter of ₹110.00 to ₹118.00 per share with a total issue size of ₹69.04 crore, the offering generated a cumulative application demand value of ₹189.93 crore (calculated at the upper price band cap of ₹118 per share) clearing through central registries.

With bidding officially completed, investor attention now shifts directly to final allotment probabilities, unlisted grey market trends, diagnostic equipment capex expansion across South India, and the upcoming stock exchange debut scheduled for Wednesday, August 19, 2026.

Here is an extended, plain-English human breakdown covering final subscription metrics, business operations across radiology and pathology, financial health, grey market performance, and the upcoming allotment schedule.

1. Final Subscription Data: Category-by-Category Breakdown

By 5:00 PM on Day 3, central processing registries compiled valid application tokens for 1,60,95,600 equity shares against the net offered size of 41,54,400 equity shares.

At the upper price band cap of ₹118 per share, this represents an aggregate primary demand value of ₹189.93 crore.

The table below breaks down final demand metrics across all investor categories:

+-----------------------------------------------------------------------------------+
|                  PRAMODINI MEDICARE LIMITED: FINAL SUBSCRIPTION DATA              |
+-------------------+-----------------+------------------+------------------+-------+
| Category          | Shares Offered  | Shares Bid For   | Final Sub (x)    | Value |
+-------------------+-----------------+------------------+------------------+-------+
| QIB (Institutions)| 11,71,200       | 42,82,800        | 3.66x            | ₹50.54Cr
| NII / HNI (Wealth)| 9,60,000        | 47,59,200        | 4.96x            | ₹56.16Cr
| Retail (RII)      | 20,23,200       | 70,53,600        | 3.49x            | ₹83.23Cr
| Market Maker      | 3,36,000        | —                | —                | —     |
+-------------------+-----------------+------------------+------------------+-------+
| Total Net Offer   | 41,54,400       | 1,60,95,600      | 3.87x            | ₹189.93Cr
+-------------------+-----------------+------------------+------------------+-------+

Analyzing the Final Category Inflows:

  • Non-Institutional Investors (NII / HNI - 4.96x): High-net-worth wealth accounts and family offices spearheaded the final-day volume jump, advancing sharply from 0.21x on Day 2 to close at 4.96 times. HNI applicants submitted electronic orders for 47,59,200 shares worth ₹56.16 crore. Both small-HNI and big-HNI brackets saw active multi-lot application submissions.
  • Qualified Institutional Buyers (QIB - 3.66x): Institutional funds expanded their order cards significantly on the final afternoon, moving from 1.81x on Day 2 to 3.66 times. Institutional desks submitted bids for 42,82,800 shares worth ₹50.54 crore.
  • Retail Individual Investors (RII - 3.49x): Everyday retail accounts maintained steady momentum throughout the final session, moving from 0.72x on Day 2 to close at 3.49 times. Retail participants submitted bids for 70,53,600 shares (2,939 application lots) worth ₹83.23 crore. Under the issue rules, retail applicants faced a minimum lot requirement of 2 lots (2,400 shares), requiring an upfront layout of ₹2,83,200 at ₹118 per share.
  • Anchor Investor Placement: Prior to opening the public issue, Pramodini Medicare successfully placed 13,60,800 shares with institutional anchor investors on Tuesday, August 11, 2026, raising ₹16.06 crore at ₹118 per share.
  • Market Maker Block: A dedicated block of 3,36,000 shares (~₹3.96 crore) is allocated to designated market makers (Shreni Shares & Rainbow Securities) to provide secondary market liquidity support post-listing.

2. Unlisted Grey Market Premium (GMP) & Expected Listing Gains

With final bidding figures locked in at 3.87x overall coverage, sentiment in the unlisted grey market corridors is currently trading near flat to modest levels:

  • Issue Price Band: ₹110.00 to ₹118.00 per share
  • Current Grey Market Premium (GMP): Tracking around +₹3.00 to +₹6.00 per share
  • Estimated Listing Price Range: Expected debut counter level of ₹121.00 to ₹124.00 per share
  • Projected Listing Gain Margin: Indicating an estimated listing upside of ~2.54% to 5.08%
  • Retail Application Lot Size: 2 Lots / 2,400 Shares (Minimum Investment: ₹2,83,200)

(Note: Grey market premiums represent informal, off-exchange quotes traded among dealers. They move based on daily market mood and should not be treated as a guaranteed listing price.)

3. Business Overview: What Does Pramodini Medicare Do?

Incorporated in September 2000 and headquartered in Vijayawada, Andhra Pradesh, Pramodini Medicare Limited is a multi-specialty diagnostic, imaging, and clinical pathology services provider.

Starting as a standalone diagnostic center, the company has evolved into a technology-enabled, multi-state diagnostic services platform operating across radiology, advanced nuclear medicine, and automated clinical pathology across Tier-1, Tier-2, and Tier-3 cities in South India.

+-----------------------------------------------------------------------------------+
|                     PRAMODINI MEDICARE BUSINESS AT A GLANCE                       |
+-----------------------------------+-----------------------------------------------+
| Core Focus Area                   | Integrated Medical Diagnostics & Imaging      |
|                                   | (Radiology, PET-CT, MRI, Pathology Labs)      |
+-----------------------------------+-----------------------------------------------+
| Diagnostic Modality Portfolio     | MRI, CT Scans, PET-CT, SPECT, Mammography,    |
|                                   | Ultrasound, DEXA, X-Ray & Full Pathology Tests|
+-----------------------------------+-----------------------------------------------+
| Operating Business Model          | Public-Private Partnerships (PPP), Hospital   |
|                                   | Strategic Alliances & Standalone Centers      |
+-----------------------------------+-----------------------------------------------+
| Primary Geographic Footprint      | Andhra Pradesh, Telangana & South India       |
+-----------------------------------+-----------------------------------------------+
| Head Office                       | Vijayawada, Andhra Pradesh                    |
+-----------------------------------+-----------------------------------------------+

Core Competitive Moats:

1. Comprehensive Advanced Modality Infrastructure

Unlike basic blood testing collection booths, Pramodini Medicare operates high-end imaging modalities—including high-field MRI scanners, multi-slice CT machines, PET-CT scanners for oncology diagnostics, and SPECT nuclear medicine systems. Offering radiology and pathology under one roof creates high doctor referral loyalty and multi-test ticket sizes.

2. Hybrid Asset-Light Partnership Model

The company expands its reach through Public-Private Partnerships (PPP) with state health departments, hospital-based diagnostic arrangements, and strategic alliances with medical colleges and public sector undertakings (PSUs). Operating diagnostic hubs inside existing hospitals lowers real estate capex and provides immediate patient traffic.

3. Centralized Tele-Radiology & Pathology Reporting

By linking regional imaging scanners to a centralized tele-radiology network, senior radiologists and pathologists in Vijayawada can analyze scans remotely in real-time, allowing Pramodini to offer specialized reporting standards in smaller Tier-2 and Tier-3 towns without needing full-time senior specialists stationed at every remote site.

4. Detailed Financial Performance (FY24 to FY26)

An audit of the company's restated consolidated financial statements shows rapid top-line scaling along with exceptional EBITDA and net profit margins over the last three fiscal years.

+-----------------------------------------------------------------------------------+
|               PRAMODINI MEDICARE: 3-YEAR FINANCIAL PERFORMANCE                    |
+-------------------------------+-------------------+-------------------+-----------+
| Financial Metric (₹ in Cr)    | FY24              | FY25              | FY26      |
+-------------------------------+-------------------+-------------------+-----------+
| Total Revenue / Income        | 35.23             | 38.24             | 62.29     |
| Operating EBITDA              | 15.36             | 16.69             | 23.51     |
| EBITDA Margin (%)             | 43.60%            | 43.64%            | 37.75%    |
| Net Profit After Tax (PAT)    | 7.14              | 11.14             | 17.38     |
| PAT Margin (%)                | 20.27%            | 29.13%            | 27.90%    |
| Total Assets                  | 48.78             | 56.45             | 93.62     |
| Total Debt / Borrowings       | 11.96             | 10.81             | 17.85     |
| Net Worth                     | 24.75             | 35.77             | 53.15     |
| Return on Net Worth (RoNW %)  | 28.85%            | 31.14%            | 32.69%    |
+-------------------------------+-------------------+-------------------+-----------+

(Source: Restated Consolidated Financial Statements in RHP)

Key Financial Observations:

  1. Fast Top-Line Scaling: Total income expanded from ₹35.23 crore in FY24 to ₹38.24 crore in FY25, before surging 62.9% YoY to ₹62.29 crore in FY26. This revenue growth was driven by higher diagnostic patient volumes across radiology and PET-CT oncology imaging.
  2. Elite Operational Profitability: Operating EBITDA margins reached 37.75% in FY26 (EBITDA of ₹23.51 crore), while net profit after tax (PAT) jumped 56% YoY from ₹11.14 crore in FY25 to ₹17.38 crore in FY26 (PAT margin of 27.90%). Diagnostic imaging assets carry high gross operating leverage once fixed machine lease costs are covered.
  3. High Return Ratios: The company operates with high internal capital efficiency, delivering a Return on Equity / RoNW of 32.69% in FY26.

5. Structure of the Offer & Objects of the Issue

The ₹69.04 crore public issue is split into fresh capital and an offer for sale:

+-----------------------------------------------------------------------------------+
|                         IPO CAPITAL STRUCTURE BREAKDOWN                           |
+-----------------------------------+-----------------------------------------------+
| Total Issue Size                  | ₹69.04 Crore (58,51,200 Equity Shares)        |
+-----------------------------------+-----------------------------------------------+
| Fresh Issue Component             | ₹63.14 Crore (53,50,800 Equity Shares)        |
+-----------------------------------+-----------------------------------------------+
| Offer for Sale (OFS) Component    | ₹5.90 Crore (5,00,400 Equity Shares)          |
+-----------------------------------+-----------------------------------------------+
| Price Band                        | ₹110 to ₹118 per share                        |
+-----------------------------------+-----------------------------------------------+
| Face Value                        | ₹10 per share                                 |
+-----------------------------------+-----------------------------------------------+
| Market Maker Block                | 3,36,000 Shares (₹3.96 Crore Value)           |
+-----------------------------------+-----------------------------------------------+
| Lead Manager (BRLM)               | Smart Horizon Capital Advisors Private Ltd    |
+-----------------------------------+-----------------------------------------------+
| Registrar to the Issue            | Purva Sharegistry (India) Private Limited     |
+-----------------------------------+-----------------------------------------------+

(Source: Official Red Herring Prospectus)

How Will Fresh Issue Capital Be Deployed?

Out of the ₹69.04 crore total issue size, ₹63.14 crore represents fresh primary capital coming directly onto the company balance sheet. Pramodini Medicare will deploy these proceeds into two primary areas:

  1. CAPEX for Advanced Medical Equipment Purchase (₹45.15 Crore / 71.5%): Directed to acquire advanced MRI scanners, CT machines, PET-CT systems, and automated pathology analyzers to upgrade existing centers and outfit proposed diagnostic centers in Andhra Pradesh and Telangana.
  2. General Corporate Purposes & Strategic Acquisitions (₹17.99 Crore / 28.5%): Allocated to support administrative run-rates, brand building, and explore inorganic acquisitions of smaller regional diagnostic labs.

Understanding the Offer for Sale (OFS):

The remaining ₹5.90 crore is an Offer for Sale (OFS) of 5,00,400 shares by promoter selling shareholders. OFS proceeds go directly to the selling shareholders.

6. Valuation Analysis & Peer Group Comparison

At the upper price band cap of ₹118 per share, Pramodini Medicare is priced at a trailing Price-to-Earnings (P/E) multiple of 11.34x based on its pre-issue FY26 basic EPS of ₹10.41 (and 14.97x based on post-issue diluted EPS of ₹7.88), establishing a post-issue corporate market capitalization of approximately ₹260.14 crore.

Let's compare this with listed diagnostic and healthcare services peers in India:

+-----------------------------------------------------------------------------------+
|                        PEER GROUP VALUATION COMPARISON                            |
+-----------------------------------+--------------------+--------------------------+
| Company Name                      | Trailing P/E (x)   | Primary Focus / Model    |
+-----------------------------------+--------------------+--------------------------+
| Pramodini Medicare (At ₹118)      | ~14.97x (Post-IPO) | Diagnostic & Imaging     |
| Dr. Lal PathLabs Ltd              | ~62.10x            | Pathology Lab Network    |
| Metropolis Healthcare Ltd         | ~54.30x            | Diagnostic Testing Chain |
| Krsnaa Diagnostics Ltd            | ~16.74x            | PPP Diagnostic Major     |
| Invicta Diagnostic Ltd            | ~13.62x            | Regional Diagnostics     |
+-----------------------------------+--------------------+--------------------------+

(Source: Peer Comparison Data in Prospectus)

Valuation Summary:

At 14.97x post-issue FY26 trailing earnings, Pramodini Medicare enters the exchange portals at an attractive valuation structure compared to listed PPP diagnostic major Krsnaa Diagnostics (~16.7x P/E) and major national pathology chains (~54x–62x P/E).

Given its ₹62.29 crore revenue scale, 37.75% EBITDA margins, 32.69% RoNW returns, and PAT reaching ₹17.38 crore, the ~15.0x post-issue P/E multiple leaves a healthy fundamental margin of safety for incoming public investors.

7. Core Strengths vs. Key Business Risks

Investors tracking post-allotment developments should consider the following operational factors:

Key Strengths:

  • Disciplined Valuation (14.97x Post-IPO P/E): Priced at ~15.0x post-issue earnings, offering a significant valuation discount compared to listed national diagnostic peers.
  • Balanced 3.87x Final Coverage: Closing with 4.96x HNI, 3.66x QIB, and 3.49x retail coverage reflects solid, well-rounded market participation.
  • Outstanding Operating Margins: Delivering a 37.75% EBITDA margin and a 27.90% PAT margin in FY26.
  • Strong Return Ratios: Return on Net Worth (RoNW) standing at 32.69%.

Key Risk Factors:

  • Geographic Concentration Risk: A substantial portion of annual operating revenue originates from diagnostic centers in Andhra Pradesh and Telangana, leaving operations sensitive to regional regulatory or healthcare policy shifts.
  • Medical Equipment Obsolescence: Radiology and nuclear medicine equipment require ongoing capital expenditure for technology upgrades and maintenance contracts.
  • High Retail Application Threshold: The minimum investment required for retail applicants was ₹2,83,200 (2 lots / 2,400 shares), which restricted participation from smaller retail accounts.

8. Allotment Architecture & Final Listing Timeline

With bidding officially completed today, here is the upcoming schedule for allotment finalization and stock exchange listing:

  • Bidding Window Close Date: Friday, August 14, 2026 (Status: Bidding Closed)
  • Basis of Allotment Finalization: Monday, August 17, 2026
  • Refund Initiations & Unblocking of Bank Funds: Tuesday, August 18, 2026
  • Credit of Equity Shares to Demat Accounts: Tuesday, August 18, 2026
  • Official Stock Exchange Listing (NSE SME): Wednesday, August 19, 2026
  • Designated Registrar: Purva Sharegistry (India) Private Limited

How to Check Your Allotment Status:

When allotment details go live on Monday, August 17, 2026, applicants can check their status by entering their PAN card number or Application ID on the Purva Sharegistry Portal or directly on the official NSE website under the SME allotment section.

Conclusion

Pramodini Medicare has concluded its public offering with a solid 3.87x overall subscription (~₹189.93 crore total demand), driven by 4.96x HNI interest, 3.66x QIB demand, and 3.49x retail participation.

With ₹63.14 crore in fresh capital moving into new radiology equipment and diagnostic expansion, 37.8% EBITDA margins, 32.7% RoNW returns, and an attractive 14.97x post-issue trailing P/E valuation, the company is set for its NSE SME exchange debut on Wednesday, August 19.

Post Excerpt

A complete final day analysis of Pramodini Medicare Ltd’s IPO closing books. Overall subscription reached 3.87x, led by 4.96x in HNIs, 3.66x in QIBs, and 3.49x in retail. Includes a full review of company financials, PET-CT radiology and pathology moats, grey market trends (+₹3–₹6), equipment capex plans, allotment schedule, and valuation comparison ahead of its August 19 debut.